CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.480
-0.080 (-3.13%)
At close: Jul 29, 2026, 4:00 PM EDT
2.412
-0.068 (-2.75%)
After-hours: Jul 29, 2026, 6:21 PM EDT
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α.
Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis.
CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CervoMed Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | John Alam |
Contact Details
Address: 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States | |
| Phone | 617 744 4400 |
| Website | cervomed.com |
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 15713L109 |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder and Director |
| William Robert Elder J.D. | Chief Financial Officer, General Counsel and Corporate Secretary |
| Kelly Blackburn M.H.A. | Executive Vice President of Clinical Development |
| Dr. Marinus Verwijs Ph.D. | Executive Vice President of Technical Operations |
| Dr. Mark A. De Rosch Ph.D. | Executive Vice President of Regulatory, Government Affairs and Program Management |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
| Dr. Matthew Winton Ph.D. | Chief Commercial and Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 14, 2026 | 8-K | Current Report |
| Jul 10, 2026 | EFFECT | Notice of Effectiveness |
| Jul 10, 2026 | 424B3 | Prospectus |
| Jul 9, 2026 | 8-K | Current Report |
| Jul 8, 2026 | SCHEDULE 13G/A | Filing |
| Jul 6, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 26, 2026 | SCHEDULE 13G | Filing |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 424B5 | Filing |
| Jun 22, 2026 | 8-K | Current Report |